- Home
- ELUT vs NRXS Comparison
ELUT vs NRXS Comparison
Compare ELUT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELUT | NRXS |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 46.3M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ELUT | NRXS |
|---|---|---|
| Price | $1.09 | $6.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 189.1K | 129.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.14 | ★ 72.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,375,000.00 | $2,685,925.00 |
| Revenue This Year | $26.95 | $31.05 |
| Revenue Next Year | $24.84 | $146.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.18 |
| 52 Week Low | $0.50 | $1.33 |
| 52 Week High | $3.46 | $6.80 |
Technical Indicators
Market Signals| Indicator | ELUT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 71.56 |
| Support Level | $0.86 | $2.32 |
| Resistance Level | $1.39 | N/A |
| Average True Range (ATR) | 0.15 | 0.49 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 25.00 | 74.96 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).